Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of HRS-7249 in hyperlipidemia
CTR20263265Phase 2Active
- Sponsor
- Tuojie Biotech
- Start
- Sep 2026
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7249 in hyperlipidemia, hypertriglyceridemia, sponsored by Tuojie Biotech. Started Sep 2026; status: active.
02
Drugs
HRS-7249
03
Conditions
hyperlipidemiahypertriglyceridemia
Beyond the preview
Go deeper on CTR20263265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263265.